Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2003

View Archived Issues

High doses of interferon beta-1b effective in early relapsing-remitting MS

Atorvastatin reduces cardiovascular events in hypertensive patients with average cholesterol levels

New data on urokinase in intracerebral hematoma

Protective effects against malaria reported for a novel primaquine analogue

Antitumor acridine derivatives prepared and tested at Servier

Three series of IBAT inhibitors identified by AstraZeneca scientists

Novel glucose-lowering agents in Sankyo research pipeline

GSK-3beta or dual GSK-3beta/CDK5 inhibitors for use in AD and other disorders

BMS researchers present new CRF antagonists with utility in anxiety, depression, etc.

Triapine evaluated clinically in combination with cytarabine for leukemia

Macrocyclic modulators of c-fos expression and their use in cancer therapy

Regenecor established to acquire PPL subsidiary

Genmab reviews developments in 2002

Gastrointestinal effects of the kappa opioid receptor agonist asimadoline

A humanized anti-EGFR monoclonal antibody reported safe in advanced epithelial cancer

Potential use of mozavaptan plus furosemide for treating edema and hyponatremia

Activa Therapy receives humanitarian device exemption for dystonia

Ortho-McNeil to acquire Axert marketing rights

Medarex and Pfizer form antibody development partnership

Praecis submits IND to begin phase I trial of PPI-2458 in NHL

GlaxoSmithKline files IND for topotecan TCS

FDA approves Vigamox

Achillion and Phytobiotech to discover drugs for infectious disease

Merger of Pfizer and Pharmacia expected to result in major synergies

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...